This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Rapivab

CSL Limited

Drug Names(s): intravenous peramivir, PeramiFlu (S. Korea), peramivir injection, Rapiacta (Japan), S-021812

Description: Peramivir injection is an influenza neuraminidase inhibitor that, in preclinical studies, has shown potent, broad-spectrum activity against multiple strains of flu, including the H5N1 virus.

Neuraminidase is an enzyme essential for the influenza virus to replicate and infect its hosts. The enzyme neuraminidase is responsible for the release of particles from infected cells. These particles then spread the disease and may also assist in spreading the virus through the mucus allowing it to escape the host through a sneeze or a cough, and infect others.

Deal Structure: Green Cross and BioCryst
In June 2006, BioCryst and Green Cross entered into an agreement that granted Green Cross the right to develop and commercialize peramivir in South Korea. As part of the agreement, Green Cross paid to BioCryst a one-time license fee. BioCryst will receive a double-digit royalty on all commercial sales, with the royalty rate being higher for non-commercial sales made to the S. Korean Government.

Shionogi and BioCryst
In March 2007, BioCryst and Shionogi announced that they entered into an exclusive license agreement to develop and commercialize peramivir in Japan. Under the terms of the agreement Shionogi will obtain rights to injectable formulations of peramivir in Japan in exchange for a $14 million up-front payment. BioCryst may also receive future clinical event milestone payments (up to $21 million) and commercial event milestone payments (up to $95 million) in addition to double digit (between 10 and 20% range) royalty payments on...See full deal structure in Biomedtracker

Partners: Shionogi & Co. Ltd. Merck KGaA Green Cross Corporation BioCryst Pharmaceuticals, Inc.


Rapivab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug